Impel Pharmaceuticals Inc. (IMPL) |
|
1.11 0.04 (3.74%)
|
03-22 10:47 |
|
Open: |
1.05 |
Pre. Close: |
1.07 |
|
High:
|
1.1399 |
Low:
|
1.05 |
|
Volume:
|
5,557 |
Market Cap:
|
26(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 10:46:51 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.47 One year: 3.34 |
| Support: |
Support1: 0.92 Support2: 0.77 |
| Resistance: |
Resistance1: 2.12 Resistance2: 2.85 |
| Pivot: |
1.15  |
| Moving Average: |
MA(5): 1.04  MA(20): 1.23
MA(100): 2.87 MA(250): 5.42 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 22.8 %D(3): 17.8 |
| RSI: |
RSI(14): 32.7 |
| 52-week: |
High: 10.75 Low: 0.92 |
| Average Vol(K): |
3-Month: 40 (K) 10-Days: 39 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMPL ] has closed above bottom band by 46.9%. Bollinger Bands are 49.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.08 - 1.09 |
1.09 - 1.09 |
|
Low:
|
1.01 - 1.01 |
1.01 - 1.02 |
|
Close:
|
1.06 - 1.07 |
1.07 - 1.08 |
|
Company Description |
|
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington. |
Headline News |
Mon, 20 Mar 2023
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023 - Marketscreener.com
Thu, 16 Mar 2023
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses ... - Nasdaq
Wed, 08 Mar 2023
Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates - Nasdaq
Tue, 07 Mar 2023
Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass ... - Nasdaq
Fri, 03 Mar 2023
Impel Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire
Thu, 23 Feb 2023
Healthcare Stocks on the Move Thursday: OCEA, AMAM, ELEV, PYXS, ORGS, IBIO, IMPL, CMMB - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
-66 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
2.374e+007 (%) |
|
% Held by Institutions
|
7.39e+006 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-23000 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-4.33 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
84.9 |
|
Return on Equity (ttm)
|
-49.2 |
|
Qtrly Rev. Growth
|
8.22e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.6 |
|
Qtrly Earnings Growth
|
-8.799e+007 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.27 |
|
Price to Sales
|
287.82 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
238050 |
|
Forward Dividend
|
174450 |
|
Dividend Yield
|
20940400% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
